KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Interest Expenses (2017 - 2022)

Sarepta Therapeutics (SRPT) has 6 years of Interest Expenses data on record, last reported at $12.7 million in Q4 2022.

  • For Q4 2022, Interest Expenses rose 13.77% year-over-year to $12.7 million; the TTM value through Sep 2023 reached $12.7 million, down 75.44%, while the annual FY2023 figure was $22.0 million, 58.67% down from the prior year.
  • Interest Expenses reached $12.7 million in Q4 2022 per SRPT's latest filing, up from $8.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $16.0 million in Q2 2022 and bottomed at -$7.5 million in Q4 2018.
  • Average Interest Expenses over 5 years is $9.6 million, with a median of $11.0 million recorded in 2020.
  • The widest YoY moves for Interest Expenses: up 2962.03% in 2018, down 1224.51% in 2018.
  • A 5-year view of Interest Expenses shows it stood at -$7.5 million in 2018, then increased by 1.07% to -$7.4 million in 2019, then skyrocketed by 245.36% to $10.8 million in 2020, then increased by 3.8% to $11.2 million in 2021, then grew by 13.77% to $12.7 million in 2022.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $12.7 million in Q4 2022, $8.7 million in Q3 2022, and $16.0 million in Q2 2022.